Cargando…

Difficult to control atopic dermatitis

Difficult to control atopic dermatitis (AD) presents a therapeutic challenge and often requires combinations of topical and systemic treatment. Anti-inflammatory treatment of severe AD most commonly includes topical glucocorticosteroids and topical calcineurin antagonists used for exacerbation manag...

Descripción completa

Detalles Bibliográficos
Autores principales: Darsow, Ulf, Wollenberg, Andreas, Simon, Dagmar, Taïeb, Alain, Werfel, Thomas, Oranje, Arnold, Gelmetti, Carlo, Svensson, Ake, Deleuran, Mette, Calza, Anne-Marie, Giusti, Francesca, Lübbe, Jann, Seidenari, Stefania, Ring, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646539/
https://www.ncbi.nlm.nih.gov/pubmed/23663504
http://dx.doi.org/10.1186/1939-4551-6-6
_version_ 1782268609487175680
author Darsow, Ulf
Wollenberg, Andreas
Simon, Dagmar
Taïeb, Alain
Werfel, Thomas
Oranje, Arnold
Gelmetti, Carlo
Svensson, Ake
Deleuran, Mette
Calza, Anne-Marie
Giusti, Francesca
Lübbe, Jann
Seidenari, Stefania
Ring, Johannes
author_facet Darsow, Ulf
Wollenberg, Andreas
Simon, Dagmar
Taïeb, Alain
Werfel, Thomas
Oranje, Arnold
Gelmetti, Carlo
Svensson, Ake
Deleuran, Mette
Calza, Anne-Marie
Giusti, Francesca
Lübbe, Jann
Seidenari, Stefania
Ring, Johannes
author_sort Darsow, Ulf
collection PubMed
description Difficult to control atopic dermatitis (AD) presents a therapeutic challenge and often requires combinations of topical and systemic treatment. Anti-inflammatory treatment of severe AD most commonly includes topical glucocorticosteroids and topical calcineurin antagonists used for exacerbation management and more recently for proactive therapy in selected cases. Topical corticosteroids remain the mainstay of therapy, the topical calcineurin inhibitors tacrolimus and pimecrolimus are preferred in certain locations. Systemic anti-inflammatory treatment is an option for severe refractory cases. Microbial colonization and superinfection contribute to disease exacerbation and thus justify additional antimicrobial / antiseptic treatment. Systemic antihistamines (H1) may relieve pruritus but do not have sufficient effect on eczema. Adjuvant therapy includes UV irradiation preferably of UVA1 wavelength. “Eczema school” educational programs have been proven to be helpful.
format Online
Article
Text
id pubmed-3646539
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher World Allergy Organization
record_format MEDLINE/PubMed
spelling pubmed-36465392013-05-08 Difficult to control atopic dermatitis Darsow, Ulf Wollenberg, Andreas Simon, Dagmar Taïeb, Alain Werfel, Thomas Oranje, Arnold Gelmetti, Carlo Svensson, Ake Deleuran, Mette Calza, Anne-Marie Giusti, Francesca Lübbe, Jann Seidenari, Stefania Ring, Johannes World Allergy Organ J Review Difficult to control atopic dermatitis (AD) presents a therapeutic challenge and often requires combinations of topical and systemic treatment. Anti-inflammatory treatment of severe AD most commonly includes topical glucocorticosteroids and topical calcineurin antagonists used for exacerbation management and more recently for proactive therapy in selected cases. Topical corticosteroids remain the mainstay of therapy, the topical calcineurin inhibitors tacrolimus and pimecrolimus are preferred in certain locations. Systemic anti-inflammatory treatment is an option for severe refractory cases. Microbial colonization and superinfection contribute to disease exacerbation and thus justify additional antimicrobial / antiseptic treatment. Systemic antihistamines (H1) may relieve pruritus but do not have sufficient effect on eczema. Adjuvant therapy includes UV irradiation preferably of UVA1 wavelength. “Eczema school” educational programs have been proven to be helpful. World Allergy Organization 2013-03-14 /pmc/articles/PMC3646539/ /pubmed/23663504 http://dx.doi.org/10.1186/1939-4551-6-6 Text en Copyright ©2013 Darsow et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Darsow, Ulf
Wollenberg, Andreas
Simon, Dagmar
Taïeb, Alain
Werfel, Thomas
Oranje, Arnold
Gelmetti, Carlo
Svensson, Ake
Deleuran, Mette
Calza, Anne-Marie
Giusti, Francesca
Lübbe, Jann
Seidenari, Stefania
Ring, Johannes
Difficult to control atopic dermatitis
title Difficult to control atopic dermatitis
title_full Difficult to control atopic dermatitis
title_fullStr Difficult to control atopic dermatitis
title_full_unstemmed Difficult to control atopic dermatitis
title_short Difficult to control atopic dermatitis
title_sort difficult to control atopic dermatitis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646539/
https://www.ncbi.nlm.nih.gov/pubmed/23663504
http://dx.doi.org/10.1186/1939-4551-6-6
work_keys_str_mv AT darsowulf difficulttocontrolatopicdermatitis
AT wollenbergandreas difficulttocontrolatopicdermatitis
AT simondagmar difficulttocontrolatopicdermatitis
AT taiebalain difficulttocontrolatopicdermatitis
AT werfelthomas difficulttocontrolatopicdermatitis
AT oranjearnold difficulttocontrolatopicdermatitis
AT gelmetticarlo difficulttocontrolatopicdermatitis
AT svenssonake difficulttocontrolatopicdermatitis
AT deleuranmette difficulttocontrolatopicdermatitis
AT calzaannemarie difficulttocontrolatopicdermatitis
AT giustifrancesca difficulttocontrolatopicdermatitis
AT lubbejann difficulttocontrolatopicdermatitis
AT seidenaristefania difficulttocontrolatopicdermatitis
AT ringjohannes difficulttocontrolatopicdermatitis